2 most recent filings and news items mentioning VVOS. Updated every 60 seconds.
OfferingJun 16, 2026Neutral
Vivos Therapeutics announced its intent to file a registration statement for a proposed rights offering that would distribute transferable subscription rights to shareholders, with an exercise price of at least $1.25 per share or 20% above market price. The offering structure inc
View filing at SEC.gov →
OfferingJun 8, 2026Neutral
Vivos Therapeutics issued a convertible promissory note for up to $5 million to V-CO Investors 4 LLC dated May 7, 2026, with an initial $500,000 advance to fund operations ahead of an anticipated $5.5 million equity financing. The note carries a 10% bridge financing fee and 15% i
View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.